| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000034314 |
| Receipt No. | R000039119 |
| Scientific Title | Evaluation of autonomic nervous system before and after inhalation of the fragrant component added to ethanol water. |
| Date of disclosure of the study information | 2018/09/28 |
| Last modified on | 2020/10/09 (Ver. 4) |
| Basic information | ||
| Public title | Evaluation of autonomic nervous system before and after inhalation of the fragrant component added to ethanol water. | |
| Acronym | Evaluation of autonomic nervous system before and after inhalation of the fragrant component added to ethanol water. | |
| Scientific Title | Evaluation of autonomic nervous system before and after inhalation of the fragrant component added to ethanol water. | |
| Scientific Title:Acronym | Evaluation of autonomic nervous system before and after inhalation of the fragrant component added to ethanol water. | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adult | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Evaluation of action to human mind and body by smelling ethyl caproate and isoamyl acetate, those are primary ginjo-aroma of sake, then discover and use new knowledge of sake fragrance. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Evaluation of autonomic nervous system |
| Key secondary outcomes | Multifaceted emotional state scale shortened version
VAS questionnaire about change of feeling VAS questionnaire about fragrance VAS questionnaire about sake |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Smell the scent of 2 kinds of component (A,B) in order A and B. | |
| Interventions/Control_2 | Smell the scent of 2 kinds of component (A,B) in order B and A. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | (1) Females aged 25 to 45 years old.
(2)Subjects who like sake, especially ginjo-sake and have experience of drinking sake. (3) Subjects who show understanding of the clinical study procedures and agreement with participating the study by written informed consent. |
|||
| Key exclusion criteria | (1)Subjects who dislike the scent of sake.
(2)Subjects who can't drink alcohol or who can drink alcohol little. (3) Subjects who have smoking habit. (4) Subjects who are cold-sensitive constitution. (including subjects like that who feel cold on their hands and foots even in summer) (5) During the past month, subjects who have been received medication for the treatment of diseases. (6) During the past month, subjects who have been received treatment of pollen allergy. (7) Subjects who have stuffy nose from allergic rhinitis or who can't distinguish scent. (8) Subjects who have previous and/or current medical history of serious disease in liver, kidney, heart, lung and/or blood. (9) Subjects with high blood pressure symptoms such as systolic blood pressure of 160 mmHg and more or diastolic blood pressure of 100 mmHg and more. (10) Pregnant or expected pregnant, or lactating women. (11) Subjects who have symptom of dermatologic disease such as atopic dermatitis. (12) Subjects who have undergone surgery on investigation objective portion within the past 6 months. (13) Subjects who are participating the other clinical tests of medicines or foods. Subjects who participated other clinical tests of medicines or foods within a month prior to the current study. (14) Subjects who themselves and/or their family are working for a company that develops, manufactures or sells alcoholic beverages, health / functional foods and cosmetics. (15) Others who have been determined ineligible by investigator. |
|||
| Target sample size | 22 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Planning & Sales Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| Homepage URL | |||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Sponsor | |
| Institute | CPCC Company Limited |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Gekkeikan Sake Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| Address | 2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan |
| Tel | 03-5297-5548 |
| IRB@cpcc.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039119 |